36 results on '"Bonneterre J"'
Search Results
2. Is Anastrozole Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer?
3. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
4. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
5. Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.
6. Prospective follow-up of 96 patients with breast cancer with leptomeningeal metastasis recruited from 2007 to 2010.
7. Is adjuvant chemotherapy useful in lobular breast cancer (LBC)?
8. Value of CA 15-3 detection in cerebrospinal fluid (CSF) of breast cancer leptomeningeal metastases.
9. KI 67 in patients (pts) with breast cancer (BC) younger than age 35: A comparison with older patients treated in a single institution.
10. Nasal septum perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
11. Pathological characteristics and prognosis of a cohort of 74 patients (pts) with breast cancer (BC) with neoplastic meningitis (NM).
12. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.
13. Prediction of response to neoadjuvant therapy in breast cancer using plasma and tumor proteomic analyses.
14. Is the maximal tolerated dose still the best primary endpoint? Analysis of 288 dose-seeking phase I trials
15. Determinants of accrual period of time in dose escalating phase I trials
16. Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine
17. GEP01: A phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): A FNCLCC Group of early phase trials study
18. Development and validation of a prediction model for early death among cancer patients participating in phase I clinical trials of new cytotoxic agents
19. Correlation between clinical response according to WHO criteria and pathological response according to Chevallier and Sataloff in inflammatory breast cancer (IBC)
20. Prognostic factors for cancer patients with good performance status considered for inclusion in phase I clinical trials
21. MammoSite brachytherapy for low-risk breast carcinoma: Toxicity, cosmetic evaluation and quality-of-life results of a phase II study
22. Pathological response to neoadjuvant chemotherapy for inflammatory breast cancer (IBC). Critical evaluation of Chevallier’s and Sataloff’s classifications
23. Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results
24. Chemotherapy-induced amenorrhea: Influence on disease-free survival and overall survival in receptor positive premenopausal early breast cancer patients
25. Inflammatory breast cancer (IBC): A retrospective analysis of 239 patients treated in a single institution
26. Which are the interactions between baseline body mass index (BMI), toxicity of chemotherapy (CT), and efficacy of adjuvant treatments? 9-year follow-up results of French Adjuvant Study Group (FASG) trials
27. Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC)
28. Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials
29. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
30. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
31. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
32. Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do they remain effective over subsequent cycles?
33. Chemotherapy in advanced gastric carcinoma.
34. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
35. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
36. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.